-
November 1, 2023 Single Dose Of Next-Gen Psilocybin Shows Significant Reduction In Depression, 20% No Longer Needing TreatmentThe interim results show remarkable and rapid reduction in depression symptoms compared to traditional antidepressants...
-
October 13, 2022 Math Over Myth: These Psychedelic Stocks Made Confirmed Bottoms in Q3Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS,...
-
October 6, 2022 Math Over Myth: Weekly Psychedelic Stocks News RoundupGet the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin...
-
July 29, 2022 The Real Reason Cybin Bought Entheon’s DMT Clinical TrialIn a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical....
-
June 24, 2022 This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!This week in psychedelic stock news, there are big patent developments for Compass, MindMed and...
-
June 17, 2022 Psychedelic Business Spotlight – June 17This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin...
-
June 10, 2022 Psychedelic Business Spotlight – June 10This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon;...
-
May 27, 2022 5 Next-Generation Psychedelics Entering Clinical Trials This YearModernized psychedelic medicine is coming, whether you like it or not, so here are five...
-
May 10, 2022 Why Wednesday Will Be Biggest Day of 2022 for Psychedelic InvestorsPsychedelic investors are about to see pivotal data presented on flagship programs by the titans...
-
May 2, 2022 Elon Musk Excites Psychedelic Industry CEOs with This TweetThis is one of the billionaire's most explicit acknowledgments of the power of psychedelics for...
